At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
Harry Rosen Chair, Diabetes and Regenerative Medicine ResearchSenior Scientist, McEwen Stem Cell Institute, UHNAssociate Professor, Department of Physiology, University of Toronto
Dr. Nostro joined the McEwen Stem Cell Institute (formerly the McEwen Centre for Regenerative Medicine) in September 2012 as Principal Investigator and currently holds the Harry Rosen Chair in Diabetes Regenerative Medicine Research. The objective of her research is to differentiate pluripotent stem cells into pancreatic cells, with the ultimate goal of generating functional insulin-producing β cells for transplantation in people living with type 1 diabetes, eliminating the need for daily insulin injections.
Dr. Nostro obtained a Laurea in Biology (BSc and MSc equivalent) from the University of Florence, Italy in 2000. As an undergraduate student, she participated in the Erasmus Exchange Program and joined Professor Chris Potten's laboratory at the Paterson Institute for Cancer Research, in Manchester, UK. Her stay in his laboratory sparked her interest in stem cell biology and her desire to pursue an academic career.
In 2000, with a Fellowship from the Italian National Research Council, she enrolled as a PhD student at The University of Manchester and under the supervision of Dr. Gerard Brady, studied blood stem cells and became an expert in gene expression profiling of these cells at the single cell level. After obtaining her PhD in 2004, she was drawn to study a new model system and applied for a postdoctoral position in the laboratory of Dr. Gordon Keller at Mount Sinai School of Medicine in NY, where she focused on understanding the earliest stages of blood cell formation using embryonic stem cells. After relocating to Toronto in 2007, she progressed to her scientific independency by initiating a project on pancreatic development.
Her group has defined critical pathways leading to the efficient generation and purification of stem cell-derived pancreatic progenitors. Since 2015, Dr. Nostro has been leading a multi-investigator team aimed at developing novel transplantation approaches for Type 1 Diabetes therapy.
GP2-enriched pancreatic progenitors give rise to functional beta cells in vivo and eliminate the risk of teratoma formationStem Cell Reports. 2022 Apr 12;17(4):964-978.Aghazadeh Y, Sarangi F, Poon F, Nkennor B, McGaugh EC, Nunes SS, Nostro MC.
Microvessels support engraftment and functionality of human islets and hESC-derived pancreatic progenitors in diabetes modelsCell Stem Cell. 2021 Nov 4;28(11):1936-1949.Aghazadeh Y, Poon F, Sarangi F, Wong FTM, Khan ST, Sun X, Hatkar R, Cox BJ, Nunes SS, Nostro MC.
Sufu- and Spop-mediated downregulation of hedgehog signaling promotes beta cell differentiation through organ-specific niche signalsNat Commun. 2019 Oct 11;10(1):4647.Yung T, Poon F, Liang M, Coquenlorge-Gallon S, McGaugh EC, Hui C-C, Wilson MD, Nostro MC, Kim TH.
Glycoprotein 2 is a specific cell surface marker of human pancreatic progenitorsNat Commun. 2017 Aug 24;8(1):331.Cogger KF, Sinha A, Sarangi F, McGaugh EC, Saunders D, Dorrell C, Mejia-Guerrero S, Aghazadeh Y, Rourke JL, Screaton RA, Grompe M, Streeter PR, Powers AC, Brissova M, Kislinger T, Nostro MC.
Principal Investigator: Dr. Cristina Nostro
Administrative Assistant: Jonelle Martineau
Lab Manager: Farida Sarangi
Dr. Cristina Nostro, holder of the Harry Rosen Chair in Diabetes Regenerative Medicine Research at the McEwen Centre for Regenerative Medicine, is on a mission to find a cure for Type 1 diabetes. Bringing an international flair to her scientific background (she is from Italy and has done advanced training in England and the United States), Dr. Nostro joined the McEwen Centre in 2007 as a post-doctoral fellow.
Type 1 diabetes has long been considered to be an ideal candidate for stem cell-based therapy. Her discoveries made in the McEwen Centre labs now give her the ability to produce functioning, insulin-producing beta cells. Among stem cell scientists, there is a sense that they are getting closer to a cell therapy goal, effectively making the leap from bench to bedside.
In 2015, Dr. Nostro published a groundbreaking study in Stem Cell Reports showing methods to effectively generate larger populations of pancreatic progenitor cells (essentially, pancreatic cells that can produce beta cells) using a wide range of pluripotent stem cells. Her research has shown that when these cells are transplanted into Type 1 models, they have successfully reverted glucose to normal levels. This will enable more efficient testing of these cells across a larger number of laboratories, increasing the odds – and the speed – of obtaining a cure for Type 1 diabetes.
Dr. Nostro is also using a technique that allows the insulin-producing cells that are destroyed by Type 1 diabetes to be re-created in our laboratories. This will help her understand how the disease develops and perhaps lead to more effective treatments for the condition.
"Our ultimate goal is to develop new drugs that will modify the immune system so that it ends its attack on the beta cells."